Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine,Biotechnology
Reference82 articles.
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.
https://doi.org/10.3322/caac.21387
.
2. Chen Y, Du H. The promising PARP inhibitors in ovarian cancer therapy: from olaparib to others. Biomed Pharmacother. 2018;99:552–60.
https://doi.org/10.1016/j.biopha.2018.01.094
.
3. Kurman RJ, Carcangiu ML, Herrington CS. World Health Organisation classification of tumours of the female reproductive organs. 4th revised ed. International Agency for Research on Cancer; 2014.
4. Singh N, McCluggage WG, Gilks CB. High-grade serous carcinoma of tubo-ovarian origin: recent developments. Histopathology. 2017;71(3):339–56.
https://doi.org/10.1111/his.13248
.
5. Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005;104(12):2807–16.
https://doi.org/10.1002/cncr.21536
.
Cited by
35 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献